WO2023012516 - COMPOSITIONS AND METHODS RELATED TO BLOOD-BRAIN BARRIER PENETRATION
National phase entry:
Publication Number
WO/2023/012516
Publication Date
09.02.2023
International Application No.
PCT/IB2022/000444
International Filing Date
02.08.2022
Title **
[English]
COMPOSITIONS AND METHODS RELATED TO BLOOD-BRAIN BARRIER PENETRATION
[French]
COMPOSITIONS ET MÉTHODES SE RAPPORTANT À LA PÉNÉTRATION D'UNE BARRIÈRE HÉMATO-ENCÉPHALIQUE
Applicants **
INSIGHTEC LTD.
SUNNYBROOK RESEARCH INSTITUTE
Inventors
ACHROL, Achal, Singh
LIPSMAN, Nir
MENG, Ying
ALIKACEM, Nadir
Priority Data
63/229,865
05.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4037 | |
| EPO | Filing, Examination, Granting | 64286 | |
| Japan | Filing, Examination, Granting | 4158 | |
| South Korea | Filing, Examination, Granting | 6137 | |
| USA | Filing, Examination, Granting | 16740 |
Total:
95,358
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure is directed to methods related to the delivery of antibodies targeting Her2 across the blood-brain barrier.[French]
La divulgation concerne des méthodes liées à l'administration d'anticorps ciblant Her2 à travers la barrière hémato-encéphalique.